<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667121</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000585065</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC0738</secondary_id>
    <secondary_id>07-006133</secondary_id>
    <secondary_id>NCI-2011-00406</secondary_id>
    <nct_id>NCT00667121</nct_id>
  </id_info>
  <brief_title>Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline</brief_title>
  <official_title>The Effect of Antidepressants and Gabapentin on Tamoxifen Pharmacokinetics: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood in the laboratory from patients receiving tamoxifen may&#xD;
      help doctors learn more about the effects of other drugs on the level of tamoxifen in the&#xD;
      blood.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying levels of tamoxifen in the blood of women with&#xD;
      breast cancer and in women at high risk of breast cancer who are receiving tamoxifen together&#xD;
      with venlafaxine, citalopram, escitalopram, gabapentin, or sertraline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To examine the changes in the plasma concentrations of the hydroxylated metabolite,&#xD;
           4-hydroxy tamoxifen, and endoxifen in women with known or at high risk for developing&#xD;
           breast cancer who are receiving selective serotonin reuptake&#xD;
           inhibitor/serotonin-norepinephrine reuptake inhibitor therapy comprising venlafaxine,&#xD;
           citalopram hydrobromide, escitalopram oxalate, gabapentin, or sertraline hydrochloride&#xD;
           for the treatment of hot flashes, depression, or any other medically indicated&#xD;
           condition.&#xD;
&#xD;
        -  To evaluate whether genetic variants known to affect the activity of CYP2D6, SULT1A1,&#xD;
           and other drug metabolizing enzymes (e.g., UGT's) involved in the biotransformation of&#xD;
           tamoxifen citrate affect the plasma concentrations of the hydroxylated metabolites,&#xD;
           4-hydroxy tamoxifen and endoxifen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral tamoxifen citrate and concurrent selective serotonin reuptake inhibitor&#xD;
      (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) therapy comprising oral&#xD;
      venlafaxine, citalopram hydrobromide, escitalopram oxalate, sertraline hydrochloride, or&#xD;
      gabapentin for 8-24 weeks. Treatment continues in the absence of disease progression.&#xD;
&#xD;
      Blood samples are obtained at baseline and after completion of study therapy. Samples are&#xD;
      evaluated by pharmacokinetic analysis to determine the effects of SSRI/SNRI study drugs on&#xD;
      plasma concentrations of tamoxifen and its metabolites. Plasma levels of tamoxifen citrate,&#xD;
      N-desmethyl tamoxifen, 4-OH tamoxifen, and endoxifen are measured using reverse phase high&#xD;
      performance liquid chromatography. Blood samples are also analyzed by CYP2D6 genotyping to&#xD;
      test for CYP2D6 gene variation (i.e., *3, *4, *6, *10, *17, and *41) in genes that encode&#xD;
      tamoxifen-metabolizing enzymes. Additional CYP2D6 alleles, including gene duplication and&#xD;
      gene deletion (*5) are assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 16, 2011</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Actual">May 12, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in plasma concentrations of 4-hydroxy tamoxifen and of endoxifen after ≥ 8 weeks of concurrent administration of tamoxifen citrate and a CYP2D6 inhibitor</measure>
    <time_frame>Between 8-16 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Depression</condition>
  <condition>Hot Flashes</condition>
  <condition>Psychosocial Effects of Cancer and Its Treatment</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>citalopram hydrobromide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram oxalate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gabapentin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venlafaxine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>molecular genetic technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>high performance liquid chromatography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Life expectancy ≥ 16 weeks&#xD;
&#xD;
          -  No contraindication for venlafaxine, citalopram hydrobromide, escitalopram oxalate,&#xD;
             gabapentin, or sertraline hydrochloride&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent medications that are known to inhibit&#xD;
             the CYP2D6 system&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Diagnosis of invasive or non-invasive breast cancer&#xD;
&#xD;
               -  At high risk for developing breast cancer&#xD;
&#xD;
          -  Has been receiving tamoxifen citrate for at least 4 weeks without any breaks either&#xD;
             for the prevention or the adjuvant treatment of invasive or non-invasive breast cancer&#xD;
             at a dose of 20 mg/day&#xD;
&#xD;
          -  Planning to begin medical therapy with one of the following drugs, as determined by&#xD;
             physician:&#xD;
&#xD;
               -  Venlafaxine&#xD;
&#xD;
               -  Citalopram hydrobromide&#xD;
&#xD;
               -  Escitalopram oxalate&#xD;
&#xD;
               -  Sertraline hydrochloride&#xD;
&#xD;
               -  Gabapentin&#xD;
&#xD;
          -  Agrees to continue tamoxifen citrate during the proposed minimum study period of 8&#xD;
             weeks&#xD;
&#xD;
          -  Known CYP2D6 genotype&#xD;
&#xD;
               -  Not known to be a CYP2D6 poor metabolizer (defined as homozygous for one of the&#xD;
                  following CYP2D6 null alleles: *3, *4, *5, *6) as determined from the baseline&#xD;
                  genotype test&#xD;
&#xD;
          -  Estrogen receptor-positive disease (for patients with breast cancer)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Life expectancy ≥ 16 weeks&#xD;
&#xD;
          -  Willing to return to primary site of enrollment for follow-up, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Mayo Clinic Rochester&#xD;
&#xD;
               -  Indiana University&#xD;
&#xD;
               -  University of Michigan&#xD;
&#xD;
               -  Johns Hopkins&#xD;
&#xD;
               -  Fairfax-Northern Virginia Hematology-Oncology, PC&#xD;
&#xD;
          -  No contraindication for venlafaxine, citalopram hydrobromide, escitalopram oxalate,&#xD;
             gabapentin, or sertraline hydrochloride&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent medications that are known to inhibit&#xD;
             the CYP2D6 system&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew P. Goetz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2008</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psychosocial effects of cancer and its treatment</keyword>
  <keyword>breast cancer</keyword>
  <keyword>hot flashes</keyword>
  <keyword>depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

